Tvardi Therapeutics, Inc. Common Stock
$1.63
$0.01 (+0.62%)
$1.59Day Range$1.66
Key Statistics
Market Cap
$21.61M
Shares Outstanding
13.3M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Apr 16, 2025
Round Lot
100
Locale
US
Trading Data
Day Open
$1.63
Day High
$1.66
Day Low
$1.59
Volume
121.6K
VWAP
$1.62
Prev Close
$1.62
Transactions
--
Acc. Volume
--
About Tvardi Therapeutics, Inc. Common Stock
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
PHARMACEUTICAL PREPARATIONSSIC 283412 employees3 SUGAR CREEK CTR. BLVD., SUGAR LAND, TX, 77478(713) 489-8654IPO Apr 16, 2025US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001346830
- Composite FIGI
- BBG001J2QYS9
- Share Class FIGI
- BBG001V0GHL4
- Ticker Root
- TVRD
- SIC Code
- 2834
About Tvardi Therapeutics, Inc. Common Stock (TVRD) Stock
Tvardi Therapeutics, Inc. Common Stock (TVRD) closed the 2026-09-18 session at $1.63, up 0.62% versus the previous close (+0.01). The stock opened at $1.63 and traded between $1.59 and $1.66 during that session. Session trading volume was 122K shares. The volume-weighted average price (VWAP) is $1.62.
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Tvardi Therapeutics, Inc. Common Stock has a market capitalization of $21.6 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. TVRD is listed on the XNAS exchange. The company employs approximately 12 people. Tvardi Therapeutics, Inc. Common Stock is headquartered in SUGAR LAND, TX. The recorded listing date is 2025-04-16.
On this page you can find market TVRD stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.